Treatment for Acute Pain

NUCYNTA®, designed as a next-generation short-acting opioid, offers the same unique, active molecule as NUCYNTA® ER (tapentadol) extended-release tablets, CII. NUCYNTA® is an opioid analgesic indicated for the management of moderate to severe acute pain in adults.1,2

Efficacy

See phase 3 data demonstrating the strength of NUCYNTA® for patients with moderate to severe acute pain.

KNOW MORE
Safety and Tolerability

Learn about the well‑defined tolerability profile for NUCYNTA®

KNOW MORE
Dosing

Find out how to titrate to an optimal therapeutic dose.

KNOW MORE
References
  1. Daniels SE, Upmalis D, Okamoto A, Lange C. Häeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009;25:765-776.
  2. NUCYNTA® (package insert). Titusville, NJ: Janssen Pharmaceuticals, Inc; 2009.